| Valley Retina Institute P.a. | |
|
1309 E Ridge Rd Ste 1, Mcallen, TX 78503-1518 | |
| (956) 631-8875 | |
| (956) 682-6280 |
| Full Name | Valley Retina Institute P.a. |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 1309 E Ridge Rd Ste 1, Mcallen, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225139942 | NPI | - | NPPES |
| 081170501 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | J6115 (Texas) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Provider Name | Roberto Diaz Rohena |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1972584407 PECOS PAC ID: 0648188748 Enrollment ID: I20040407001189 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Victor H Gonzalez |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1871599100 PECOS PAC ID: 5698780526 Enrollment ID: I20070731000445 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Shanna J Brown |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1467613513 PECOS PAC ID: 2961659313 Enrollment ID: I20120821000157 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Juan Arciniega |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1508153115 PECOS PAC ID: 0749591444 Enrollment ID: I20150623000040 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Hamzah Suhail Khalaf |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1376819268 PECOS PAC ID: 0345552592 Enrollment ID: I20160621000390 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Mahdi Rostamizadeh |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1053654384 PECOS PAC ID: 4082918354 Enrollment ID: I20170630001162 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Alice W Kennedy |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1396130555 PECOS PAC ID: 9335432707 Enrollment ID: I20190530002415 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Vitaliy Vladimirovich Zak |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1669566535 PECOS PAC ID: 1153381694 Enrollment ID: I20200615003109 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Noorulain Shekoh |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1699385260 PECOS PAC ID: 6800212895 Enrollment ID: I20200821000202 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Meenakshisundaram Subramanian |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1154613099 PECOS PAC ID: 6002216181 Enrollment ID: I20210610002037 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Melissa Anne Ixcamey |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1245761055 PECOS PAC ID: 5698044246 Enrollment ID: I20210621001318 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Provider Name | Vimal Sarup |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1073837787 PECOS PAC ID: 5395993836 Enrollment ID: I20221004002266 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Valley Retina Institute P.a. Po Box 4830, Edinburg, TX 78540-4830 Ph: (956) 793-8388 | Valley Retina Institute P.a. 1309 E Ridge Rd Ste 1, Mcallen, TX 78503-1518 Ph: (956) 631-8875 |
News Archive
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs.
The care of patients with complex medical needs is widely regarded as one of the key factors driving increased U.S. health costs, and it is generally accepted that 10 to 15 percent of Medicare patients account for 65 to 75 percent of all Medicare spending.
BD Diagnostics, a segment of BD, a leading global medical technology company, today introduced two new erythrocyte sedimentation rate instruments in Europe that standardise analysis for more accurate, timely results and an efficient workflow in comparison to a manual Westergren method. This next generation of BD ESR instruments results in improved patient care in the laboratory or point of care setting.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today that it has signed a binding agreement for the acquisition of VaxDesign, a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system.
› Verified 2 days ago